Tretinoin lotion - Ortho Dermatology

Drug Profile

Tretinoin lotion - Ortho Dermatology

Alternative Names: IDP 121

Latest Information Update: 02 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Valeant Pharmaceuticals International
  • Developer Ortho Dermatologics
  • Class Antiacnes; Antineoplastics; Cyclohexenes; Keratolytics; Retinoids; Small molecules
  • Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Acne vulgaris

Most Recent Events

  • 27 Jul 2017 Valeant Pharmaceuticals International acquired Ortho Dermatologics in 2011 and changed the name of the later to Valeant Dermatology. Subsequently, in July 2017, it was rebranded to Ortho Dermatologics
  • 12 Apr 2017 Valeant Pharmaceuticals completes a phase III trial in Acne vulgaris (In adolescents, In children, In adults) in USA (Topical) (NCT02965456)
  • 20 Mar 2017 Valeant Pharmaceuticals completes a phase III trial in Acne vulgaris (In adolescents, In children, In adults) in USA (Topical) (NCT02932306)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top